Relationship between serum adiponectin and osteoprotegerin levels and coronary heart disease severity

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 11023-11029

  Zhang, H L ^a   Jin, X ^a  

^a JINING MEDICAL UNIVERSITY   (China)

Author keywords

Adiponectin; Coronary heart disease; Inflammatory factor; Ischemia factor; Osteoprotegerin

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ISCHEMIA MODIFIED ALBUMIN; LIPOPROTEIN; OSTEOPROTEGERIN; PHOSPHOLIPASE A2; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER; TNFRSF11B PROTEIN, HUMAN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; AGED; BLOOD; CORONARY ARTERY DISEASE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADIPONECTIN; AGED; BASE SEQUENCE; BIOMARKERS; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; SEVERITY OF ILLNESS INDEX;

EID: 84942108073     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.September.21.15     Document Type: Article

References (24)

1. Ai M, Otokozawa S, Asztalos BF, White CC, et al. (2011). Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis 217: 543-548.
2. Avignon A, Sultan A, Piot C, Mariano-Goulart D, et al. (2007). Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care 30: 2934-2939.
3. Baldasseroni S, Mannucci E, Orso F, Di Serio C, et al. (2012). Adiponectin in outpatients with coronary artery disease: independent predictors and relationship with heart failure. Nutr. Metab. Cardiovasc. Dis. 22: 292-299.
4. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, et al. (2006). Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 26: 2117-2124.
5. Celczynska Bajew L, Horst Sikorska W, Bychowiec B, Wykretowicz A, et al. (2011). The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol. Pol. 69: 573-578.
6. Chan DC, Watts GF, Ng TW, Uchida Y, et al. (2005). Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin. Chem. 51: 578-585.
7. Charpentier S, Ducasse JL, Cournot M, Maupas-Schwalm F, et al. (2010). Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department. Acad. Emerg. Med. 17: 27-35.
8. Dada N, Kim NW and Wolfert RL (2002). Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev. Mol. Diagn. 2: 17-22.
9. El-Mesallamy HO, Hamdy NM, Salman TM and Ibrahim SM (2012). Adiponectin and sE-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease. Angiology 63: 96-102.
10. Erbagci AB, Tarakcioglu M, Aksoy M, Kocabas R, et al. (2002). Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol. 57: 197-204.
11. Frystyk J, Berne C, Berglund L, Jensevik K, et al. (2007). Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J. Clin. Endocrinol. Metab. 92: 571-576.
12. Hasan-Ali H, Abd El-Mottaleb NA, Hamed HB, Abd-Elsayed A, et al. (2011). Serum adiponectin and leptin as predictors of the presence and degree of coronary atherosclerosis. Coron. Artery Dis. 22: 264-269.
13. Iwashima Y, Horio T, Kumada M, Suzuki Y, et al. (2006). Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am. J. Cardiol. 98: 1603-1608.
14. Kishida K, Funahashi T and Shimomura I (2012). Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr. Metab. Immune Disord. Drug Targets 12: 118-131.
15. Luo XH, Guo LJ, Xie H, Yuan LQ, et al. (2006). Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J. Bone Miner. Res. 21: 1648-1656.
16. Min X, Lemon B, Tang J, Liu Q, et al. (2012). Crystal structure of a single-chain trimer of human adiponectin globular domain. FEBS Lett. 586: 912-917.
17. Schoppet M, Sattler AM, Schaefer JR, Herzum M, et al. (2003). Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 88: 1024-1028.
18. Shah T, Casas JP, Cooper JA, Tzoulaki I, et al. (2009). Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 38: 217-231.
19. Shin JY, Shin YG and Chung CH (2006). Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 29: 1664-1666.
20. Simonet WS, Lacey DL, Dunstan CR, Kelley M, et al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
21. Udagawa N, Takahashi N, Yasuda H, Mizuno A, et al. (2000). Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinol. 141: 3478-3484.
22. Walus-Miarka M, Katra B, Fedak D, Czarnecka D, et al. (2011). Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. Int. J. Cardiol. 147: 335-336.
23. Wang ZV and Scherer PE (2008). Adiponectin, cardiovascular function, and hypertension. Hypertension 51: 8-14.
24. Yamauchi T, Kamon J, Ito Y, Tsuchida A, et al. (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769.